Patompong Ungprasert1,2, Cynthia S Crowson3,4, Sara J Achenbach4, Eva M Carmona5, Eric L Matteson3,6. 1. Division of Rheumatology, Department of Internal Medicine, Mayo Clinic College of Medicine and Science, 200 First Avenue SW, Rochester, MN, 55905, USA. P.Ungprasert@gmail.com. 2. Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand. P.Ungprasert@gmail.com. 3. Division of Rheumatology, Department of Internal Medicine, Mayo Clinic College of Medicine and Science, 200 First Avenue SW, Rochester, MN, 55905, USA. 4. Division of Biomedical Statistics and Informatics, Department of Health Science Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 55905, USA. 5. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, 55905, USA. 6. Division of Epidemiology, Department of Health Science Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 55905, USA.
Abstract
PURPOSE: There is little information about healthcare utilization for sarcoidosis. This study examined need for hospitalization as a measure of healthcare burden in this disease. METHODS: A cohort of Olmsted County, Minnesota residents diagnosed with sarcoidosis between January 1, 1976 and December 31, 2013 was identified using the resources of the Rochester Epidemiology Project. Diagnosis was made based on individual medical record review. For each sarcoidosis subject, one sex- and age-matched comparator without sarcoidosis was randomly selected from the same population. Data on hospitalizations were retrieved electronically from billing data of the Mayo Clinic, the Olmsted Medical Center, and their affiliated hospitals. These data were available from 1987 to 2015. Subjects who died or emigrated from Olmsted County prior to 1987 were excluded. RESULTS: 332 incident cases of sarcoidosis and 342 comparators were included. Hospitalization rates were significantly higher among patients with sarcoidosis than comparators [rate ratio (RR) 1.37; 95% confidence interval (CI) 1.24-1.52]. Analysis based on sex revealed a significantly increased rate among females (RR 1.60; 95% CI 1.40-1.82) but not among males (RR 1.06; 95% CI 0.91-1.25). The overall age- and sex-adjusted rates of hospitalization were stable from 1987 to 2015 for both cases and comparators. The average length of stay was similar (4.6 and 4.4 days for sarcoidosis and non-sarcoidosis hospitalizations, respectively, p = 0.87). CONCLUSION: In this population, patients with sarcoidosis had a significantly higher rate of hospitalization than patients without sarcoidosis, driven by higher rates in females.
PURPOSE: There is little information about healthcare utilization for sarcoidosis. This study examined need for hospitalization as a measure of healthcare burden in this disease. METHODS: A cohort of Olmsted County, Minnesota residents diagnosed with sarcoidosis between January 1, 1976 and December 31, 2013 was identified using the resources of the Rochester Epidemiology Project. Diagnosis was made based on individual medical record review. For each sarcoidosis subject, one sex- and age-matched comparator without sarcoidosis was randomly selected from the same population. Data on hospitalizations were retrieved electronically from billing data of the Mayo Clinic, the Olmsted Medical Center, and their affiliated hospitals. These data were available from 1987 to 2015. Subjects who died or emigrated from Olmsted County prior to 1987 were excluded. RESULTS: 332 incident cases of sarcoidosis and 342 comparators were included. Hospitalization rates were significantly higher among patients with sarcoidosis than comparators [rate ratio (RR) 1.37; 95% confidence interval (CI) 1.24-1.52]. Analysis based on sex revealed a significantly increased rate among females (RR 1.60; 95% CI 1.40-1.82) but not among males (RR 1.06; 95% CI 0.91-1.25). The overall age- and sex-adjusted rates of hospitalization were stable from 1987 to 2015 for both cases and comparators. The average length of stay was similar (4.6 and 4.4 days for sarcoidosis and non-sarcoidosis hospitalizations, respectively, p = 0.87). CONCLUSION: In this population, patients with sarcoidosis had a significantly higher rate of hospitalization than patients without sarcoidosis, driven by higher rates in females.
Authors: Lee S Newman; Cecile S Rose; Eddy A Bresnitz; Milton D Rossman; Juliana Barnard; Margaret Frederick; Michael L Terrin; Steven E Weinberger; David R Moller; Geoffrey McLennan; Gary Hunninghake; Louis DePalo; Robert P Baughman; Michael C Iannuzzi; Marc A Judson; Genell L Knatterud; Bruce W Thompson; Alvin S Teirstein; Henry Yeager; Carol J Johns; David L Rabin; Benjamin A Rybicki; Reuben Cherniack Journal: Am J Respir Crit Care Med Date: 2004-09-03 Impact factor: 21.405
Authors: Marc A Judson; Bruce W Thompson; David L Rabin; Joanne Steimel; Genell L Knattereud; Daniel T Lackland; Cecile Rose; Cynthia S Rand; Robert P Baughman; Alvin S Teirstein Journal: Chest Date: 2003-02 Impact factor: 9.410
Authors: G W Hunninghake; S Gilbert; R Pueringer; C Dayton; C Floerchinger; R Helmers; R Merchant; J Wilson; J Galvin; D Schwartz Journal: Am J Respir Crit Care Med Date: 1994-04 Impact factor: 21.405
Authors: Marilyn G Foreman; David M Mannino; Lois Kamugisha; Gloria E Westney Journal: Sarcoidosis Vasc Diffuse Lung Dis Date: 2006-06 Impact factor: 0.670
Authors: Silvia Baldacci; Michele Santoro; Anna Pierini; Lorena Mezzasalma; Francesca Gorini; Alessio Coi Journal: Int J Environ Res Public Health Date: 2022-06-21 Impact factor: 4.614
Authors: Rachel Strykowski; Divya C Patel; Manny Ribeiro Neto; Kerry M Hena; Mridu Gulati; LIsa A Maier; Karen Patterson Journal: BMJ Open Respir Res Date: 2022-07
Authors: Caitrin M Coffey; Avneek S Sandhu; Cynthia S Crowson; Sara J Achenbach; Eric L Matteson; Thomas G Osborn; Kenneth J Warrington; Ashima Makol Journal: J Rheumatol Date: 2020-11-15 Impact factor: 5.346